肾细胞癌

IF 0.4 Q4 ONCOLOGY

memo - Magazine of European Medical Oncology Pub Date : 2023-11-07 DOI:10.1007/s12254-023-00918-w

Jasmin Spiegelberg

{"title":"肾细胞癌","authors":"Jasmin Spiegelberg","doi":"10.1007/s12254-023-00918-w","DOIUrl":null,"url":null,"abstract":"Summary Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.","PeriodicalId":18379,"journal":{"name":"memo - Magazine of European Medical Oncology","volume":"30 6","pages":"0"},"PeriodicalIF":0.4000,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Renal cell carcinoma\",\"authors\":\"Jasmin Spiegelberg\",\"doi\":\"10.1007/s12254-023-00918-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Summary Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.\",\"PeriodicalId\":18379,\"journal\":{\"name\":\"memo - Magazine of European Medical Oncology\",\"volume\":\"30 6\",\"pages\":\"0\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-11-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"memo - Magazine of European Medical Oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12254-023-00918-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"memo - Magazine of European Medical Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12254-023-00918-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

肾癌分别占男性和女性所有成人恶性肿瘤的5%和3%。肾细胞癌(RCC)约占所有肾癌的80%。今年的美国临床肿瘤学会(ASCO)年会于2023年6月2日至6日在美国芝加哥举行。随着一些正在进行的研究的最新结果的发布，晚期RCC的联合治疗在ASCO 2023上继续受到关注。ASCO上有几项关于非透明肾细胞癌治疗的研究。以免疫疗法为基础的治疗方案现在是治疗罕见组织学亚型RCC的金标准。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Renal cell carcinoma

Summary Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women. Renal cell carcinoma (RCC) accounts for approximately 80% of all kidney cancer. This year’s American Society of Clinical Oncology (ASCO) Annual Meeting was held from 2–6 June 2023, in Chicago, USA. Combination therapies for advanced RCC continue to be of interest at ASCO 2023, with the presentation of updated results from some ongoing studies. There were several studies presented at ASCO looking at treatments for non clear renal cell carcinoma. Immunotherapy- based therapy regimes are now the gold standard for rare histological subtypes of RCC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

memo - Magazine of European Medical Oncology ONCOLOGY-

CiteScore

1.80

自引率

16.70%

发文量

期刊介绍： memo is the Official Journal of the Central European Cooperative Oncology Group (CECOG) and The Austrian Society of Haematology and Oncology (OeGHO). The focus of the journal "magazine of european medical oncology – memo" is to offer a professional review on current research and development in the field of hematology and oncology relevant for daily practice. Therefore, memo includes editorials and comments, peer-reviewed original reports, short reviews, case reports and controversies, articles explaining the biology of neoplasia and congress reports including qualified comments. As a European journal memo aims at highlighting the local peculiarities of various regions and at being a forum for the presentation of ongoing clinical and basic research.